Atezolizumab plus bevacizumab-induced intratumoral hemorrhage in a patient with rib metastasis from unresectable hepatocellular carcinoma

Atezolizumab plus bevacizumab-induced intratumoral hemorrhage in a patient with rib metastasis from unresectable hepatocellular carcinoma

Recently, combination therapy with atezolizumab, a humanized monoclonal antiprogrammed death ligand-1 antibody, and bevacizumab, has become available for treatment of unresectable hepatocellular carcinoma (HCC). We herein report a 73-year-old man with advanced stage HCC who developed fatigue during...

Full description

Bibliographic Details
Main Authors: Yasuhito Mitsuyama, MD, Ken Kageyama, MD, PhD, Hiroji Shinkawa, MD, PhD, Akira Yamamoto, MD, PhD, Atsushi Jogo, MD, PhD, Etsuji Sohgawa, MD, Shogo Tanaka, MD, PhD, Shigekazu Takemura, MD, PhD, Shoji Kubo, MD, PhD, Takeaki Ishizawa, MD, PhD, Yukio Miki, MD, PhD
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:Radiology Case Reports
Subjects:
Hepatocellular carcinoma
Transcatheter arterial embolization
Atezolizumab and bevacizumab
Online Access:http://www.sciencedirect.com/science/article/pii/S1930043323003849

Similar Items

Similar Items